Many myeloma patients are elderly, with the average age of diagnosis being 68. If individuals are fit and active, they can typically receive the "standard of care" drugs such as stem cell transplant or triplet drug combinations. But many individuals may be frail or have other health conditions that would required doctors to adjust treatment accordingly. Dr. Tanya Wildes, MD of the Washington University Siteman Cancer Institute shares how treatment can be modified for more frail patients and how therapy should be personalized for us all.
Thanks to our episode sponsor, Takeda Oncology.